Communiqués TAO Synergies Inc.

Actions

TAOX

US87167T3005

Blockchain & Cryptomonnaies

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
3,370 ^USD	-2,03 %		+2,43 %	-8,42 %

13/05	TAO Synergies Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
31/03	TAO Synergies Inc. publie ses résultats annuels pour l'exercice clos le 31 décembre 2025	CI

Communiqués

18/11	TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation	PR
04/11	TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds	PR
20/10/25	TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency	PR
13/10/25	TAO Synergies Announces $11 Million Private Placement	PR
22/09/25	TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)	PR
08/09/25	TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event	PR
26/08/25	TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy	PR
06/08/25	TAO Synergies Accelerates Decentralized AI Treasury Strategy with 42,111 Bittensor (TAO) Tokens Acquired and Earned Through Staking to Date	PR
01/07/25	TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today	PR
26/06/25	Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy	PR
24/06/25	Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking	PR
09/06/25	Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token	PR
23/12/24	Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength	AQ
20/12/24	Synaptogenix : Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength Form 8 K	PU
20/12/24	Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength	PR
11/09/24	Synaptogenix Announces $5.0 Million Financing	PR
18/07/24	Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury	PR
26/06/24	Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis	PR
07/05/24	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery	PR
24/04/24	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	PR
09/04/24	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	PR
03/04/24	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	PR
19/12/23	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	PR
06/12/23	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	PR
03/11/23	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology	AQ